Breaking News

Israel to Purchase 5 Million Protein-Based COVID-19 Vaccines

January 28, 2022 • 12:18 pm CST
(Precision Vaccinations News)

Maryland-based Novavax, Inc. and Israel's Ministry of Health today announced a substantial agreement to purchase NVX-CoV2373 (Nuvaxovid, CovoVax), the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.

Under the advance purchase agreement, Novavax will provide an initial 5 million doses of its vaccine with an option for Israel to purchase an additional 5 million doses.

Simultaneously, Novavax is working with the Israeli Ministry of Health to obtain the necessary authorizations.

And finalize plans for distribution in Israel pending regulatory approval.

"Israel has been at the forefront of the fight against COVID-19 and has demonstrated strong leadership throughout the pandemic," said Stanley C. Erck, President, and CEO, Novavax, n a press statement issued on January 28, 2022.

"We thank the Israeli Ministry of Health for their commitment to providing a protein-based COVID-19 vaccine option, based on well-understood technology, to the people of Israel."   

Novavax has already received conditional marketing authorization for NVX-CoV2373 in the European Union and an emergency use listing from the World Health Organization.

In 2021, Novavax submitted its complete information package to the U.S. FDA and expects to submit an authorization request after one month, in accordance with guidance from the FDA regarding the submission of all EUA COVID-19 vaccines.

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company located in Gaithersburg, MD that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. 

Our Trust Standards: Medical Advisory Committee

Share